New automated features elevate the standard of care for NeuroStar® Advanced Therapy practicesMALVERN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) --...
Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the...
MALVERN, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology...
Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease Commenced Recruitment for 540-patient Phase 2...
– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase 3 trial and study lead-in...
Masimo PSi, a Processed EEG Parameter, “Better Captured” Changes in Brain State Compared to Other Assessment MethodsIRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ:...
MARLBOROUGH, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The Spatial Biology Company®, today announced...
CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a biotechnology company dedicated to breaking through barriers...
Approval opens up a new major market for CognICA, providing a solution to the urgent requirement for large-scale early detection...
-A Phase 2a study of BAER-101 in epilepsy is planned to initiate in 2024MIAMI, Aug. 01, 2023 (GLOBE NEWSWIRE) --...
Appointment adds Dr. Powchik’s experience in the development of marketed immunotherapeutics to Vaxxinity’s leadership team CAPE CANAVERAL, Fla., July 27,...
BURLINGTON, Mass. and JERUSALEM, July 26, 2023 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Cell therapy CDMO spins out of Inceptor Bio to help innovators develop and manufacture life-saving cell therapies Kincell to be...
AC Immune SA Appoints New Chief Medical Officer Nuno Mendonça, MD appointed new Chief Medical Officer and Executive Committee memberLausanne,...
Common stock and warrants of combined company will be listed on the New York Stock Exchange American under the symbols...
Linda Burkly Editas Medicine today announced the appointment of Linda C. Burkly, Ph.D., as the Company’s Executive Vice President and...
Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-trial data in...
Talquetamab is the first therapy targeting GPRC5D to receive a positive CHMP Opinion Teclistamab, the first BCMA-targeting bispecific antibody to...
Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-trial data in...
CARLSBAD, Calif.--(BUSINESS WIRE)--Nalu Medical, Inc. (“Nalu”), a Carlsbad, California-based neurostimulation company that has miniaturized neurostimulation implants for the management of...